Background: Studies of pancreaticoduodenectomy (PD) frequently overlook diagnosis as a variable
Introduction
Although significant advancements in the perioperative care of patients undergoing pancreaticoduodenectomy (PD) have resulted in a reduction in postoperative mortality, overall postoperative morbidity remains high and relatively unchanged. [1] [2] [3] [4] [5] [6] Several studies have established soft gland texture and small duct size as consistent predictors of complications after PD. [7] [8] [9] [10] [11] [12] Importantly, both of these parameters are associated with considerable subjectivity as a result of variability in their definitions and measurement. However, the underlying diagnosis prompting surgical intervention is a non-modifiable, definitive parameter that appears to have direct association with gland texture and duct size. Chronic pancreatitis and pancreatic cancer are often characterized by firmer glands and pancreatic ductal dilation caused by fibrosis, oedema and ductal obstruction, by contrast with other diagnoses, such as duodenal, biliary and pancreatic cystic lesions. Classification by diagnosis is therefore intriguing as a potential indicator of risk for the occurrence of postoperative complications. Currently, studies of postoperative outcomes following PD, including those using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database, frequently overlook diagnosis or group patients into categories according to whether they have 'benign' or 'malignant' disease, rather than performing stratification and analyses by individual diagnoses. [13] [14] [15] Grouping patients into 'benign' or 'malignant' categories may be overly simple and may lead to the under-or overestimation of the true morbidity associated with a given diagnosis within each category. The averaging effect within each of the 'benign' and 'malignant' disease groups may encourage the false impression that no significant differences in morbidity exist between the two categories. This is because the categories of 'benign' and 'malignant' both include diagnoses classically associated with gland textures and duct sizes at each end of the spectrum. The present study was conducted with the aim of developing a more clinically relevant approach towards the identification of groups at 'high' and 'low' risk, respectively, for postoperative complications based on underlying diagnosis. Currently, several small studies have reported a relationship between diagnosis and outcomes following PD. 7, [16] [17] [18] [19] [20] [21] However, no large multicentre study has yet reported on 30-day postoperative outcomes following PD by diagnosis.
Because of the associations between pathological diagnosis and pancreatic texture and duct size, and therefore risk for complications, it can be inferred that patients undergoing PD can be easily stratified into high-and low-risk groups based on diagnosis alone without further assessment or calculation. This type of stratification is clinically useful as it can be applied at any time in the clinical course of the patient. Therefore, the present study was based on the hypotheses that postoperative morbidity and length of stay (LoS) following PD vary by diagnosis and that patients may be grouped into low-and high-risk categories.
Materials and methods

Data source
The ACS-NSQIP database is a prospectively maintained, riskadjusted outcomes database of 135 variables including 30-day morbidity and mortality in patients undergoing surgical procedures. Specific details regarding data collection, outcome variable definitions, quality control and personnel training are available on the NSQIP website. 24 
Exclusions
In an attempt to achieve mutually exclusive groups and minimize any ambiguity of diagnosis, data for patients who were identified using the aforementioned CPT codes but whose disease did not fit these ICD-9 codes were excluded. There are no ICD-9 codes that specifically identify intraductal papillary mucinous neoplasm (IPMN), serous cystic neoplasm or mucinous cystic neoplasm. Therefore, no diagnosis group exclusive to IPMN, serous cystic neoplasm and mucinous cystic neoplasm could be established. Patients with acute pancreatitis, PD without pancreaticojejunostomy, or PD with autologous islet cell transplant were excluded. Patients with any of the following preoperative conditions were also excluded: emergent surgery; American Society of Anesthesiologists (ASA) class 5 status; ventilator dependence; severe sepsis or septic shock; pneumonia; an open wound; wound infection; acute renal failure; coma; receipt of >4 units of red blood cells in the prior 72 h; renal failure; dialysis, and disseminated cancer. In an attempt to reduce confounding and to create a sample population that best represents the true risks associated with PD, patients undergoing concurrent operations not typically performed with this procedure were also excluded. Excluded concurrent operations included hepatectomy, colectomy, hysterectomy, splenectomy, hernia repair, vena cava resection, nephrectomy, etc. Patients were not excluded for common concomitant operations, such as feeding tube insertion, vein resection or reconstruction, vein harvest, central line placement and laparoscopy.
Demographic characteristics
Patient demographic characteristics identified included: gender; race/ethnicity; age; year of operation; discharge destination; body mass index (BMI); diabetes; current smoking within 1 year; dyspnoea; functional status; history of severe chronic obstructive pulmonary disease (COPD); congestive heart failure; history of myocardial infarction within the 6 months prior to operation; previous percutaneous coronary intervention; previous cardiac surgery; history of angina within the 1 month prior to surgery; hypertension requiring medication; steroid use for any chronic condition; weight loss of >10% of body weight in the previous 6 months; chemotherapy within the 30 days prior to operation; radiotherapy for malignancy within the 90 days prior to operation; preoperative creatinine, bilirubin, albumin, alkaline phosphatase, haematocrit and international normalized ratio (INR) values; wound classification, and ASA class.
Outcome variables
Patient outcome variables studied included: total operative time; 30-day mortality; hospital LoS; superficial surgical site infection (SSI); deep incisional SSI; organ space SSI; any SSI; wound disruption; pneumonia; unplanned intubation; pulmonary embolism; ventilator requirement for >48 h; progressive renal insufficiency; acute renal failure; urinary tract infection (UTI); stroke or cerebral vascular accident (CVA) with neurological deficit; cardiac arrest requiring cardiopulmonary resuscitation (CPR); myocardial infarction; deep vein thrombosis (DVT); sepsis or septic shock; reoperation; unplanned readmission; number of complications; overall morbidity, and total relative value units (RVUs). For the purpose of this study, a prolonged LoS was indicated by discharge on or after postoperative day (PoD) 14, as previously defined. 25 Transfusion was not investigated as the outcome variable reported was not consistently collected across all of the years of the study. Readmission was only available as a qualitative variable for 2011. Relative value units were reviewed on a yearly basis and not totalled across all years because there are year-to-year variations in the assigned RVUs.
Complications and morbidity were then stratified as 'any' , 'major' and 'minor' . Complications defined as 'major' included: cardiac arrest requiring CPR; myocardial infarction; stroke or CVA with neurological deficit; wound disruption; deep incisional SSI; organ space SSI; sepsis or septic shock; unplanned intubation; ventilator dependency for >48 h; pneumonia; acute renal failure; progressive renal insufficiency; DVT or thrombophlebitis; pulmonary embolism, and return to the operating room. Complications defined as 'minor' included superficial SSIs and UTIs.
Statistical analysis
Rates of major morbidity were compared among diagnoses using chi-squared tests. Diagnoses were then categorized as being of 'high' or 'low' risk based on the incidence of major morbidity. Chi-squared tests, Fisher's exact tests and rank sum tests were then performed to compare demographic characteristics and postoperative outcomes in patients in the two risk groups. Multivariate logistic regression was performed to assess the impact of diagnosis on outcomes. In an attempt to control for both clinically and statistically significant risk factors, all multivariate models were adjusted for: age; race; BMI; diabetes status; smoking status; presence of dyspnoea; functional status; history of COPD; history of myocardial infarction; weight loss of >10% of body weight in the 6 months prior to operation; chemotherapy within 30 days; radiotherapy within 90 days; preoperative serum albumin; preoperative total bilirubin; preoperative alkaline phosphatase; preoperative INR; ASA class, and total operative time quartile. Univariate and multivariate secondary data analyses were also performed to assess the impacts of other clinically and statistically significant variables on outcomes. All statistical analyses were performed using sas Version 9.3 (SAS Institute, Inc., Cary, NC, USA). A P-value of <0.05 was considered to indicate statistical significance.
Results
Descriptive statistics: defining high-and low-risk diagnosis categories Within the NSQIP database, 5537 patients submitted to PD during 2005-2011 were identified and included for analysis. These included 3173 (57.3%) patients with pancreas cancer, 485 (8.8%) with chronic pancreatitis, 1181 (21.3%) with bile duct or ampullary neoplasms, 558 (10.1%) with duodenal neoplasms, and 140 (2.5%) with neuroendocrine neoplasms.
Major morbidity was greatest in patients with diagnoses of bile duct and ampullary neoplasms (33.1%), duodenal neoplasms (34.6%) and neuroendocrine neoplasms (32.1%). The incidence of major morbidity did not differ statistically among these three diagnoses (P = 0.78). Therefore, these three diagnoses were categorized as being of 'high' risk. Incidences of major morbidity were lowest among patients with pancreas cancer (23.4%) and chronic pancreatitis (23.3%), and did not differ statistically (P = 0.95). Therefore, pancreas cancer and chronic pancreatitis were categorized as being of 'low' risk ( Fig. 1) . 
Univariate outcome variables: high-versus low-risk diagnoses
Patients with high-risk diagnoses experienced slightly shorter operative times. There was no significant difference in postoperative 30-day mortality.
High-risk diagnosis patients were more likely to experience: a prolonged LoS (≥14 days); superficial SSI; deep SSI; organ space SSI; any SSI; wound disruption; progressive renal insufficiency; acute renal failure; UTI; sepsis or septic shock; return to the operating room; overall morbidity (one or more complications), and major morbidity. There was no significant difference in readmission rate (Table 2 and Fig. 2 ).
Relative value unit: high-versus low-risk diagnoses
The median RVU was observed to increase slightly over time (Table 2) . Median RVU ranged from 47.93 in 2005 to 59.38 in 2011. There was no significant difference in RVU between the high-and low-risk cohorts except in 2010, for which a higher median RVU was observed in the low-risk cohort (Table 2) .
Major complications: high-versus low-risk diagnoses
Univariate analysis demonstrated that although overall major morbidity was experienced by 26.8% of all patients studied, those with a high-risk diagnosis experienced a significantly greater incidence of major morbidity than did patients with low-risk diagnoses (33.5% versus 23.4%; P < 0.001). Multivariate analysis revealed the high-risk diagnosis category to be an independent risk factor for major complications [odds ratio (OR) 1 , and preoperative serum albumin of < 3.5 g/dl (OR 1.37, 95% CI 1.13-1.66). Fourth-quartile total operative time (≥7.25 h) in comparison with operative time of < 4.75 h was also an independent risk factor (OR 1.42, 95% CI 1.13-1.80).
Organ space SSI: high-versus low-risk diagnoses
Organ space infection was observed in 9.6% of all patients studied. High-risk diagnoses were associated with significantly more organ space infections than low-risk diagnoses (15.0% versus 6.8%; P < 0.001). Multivariate analysis revealed a high-risk diagnosis to be an independent risk factor for organ space SSIs (OR 2.57, 95% CI 2.02-3.28).
Multivariate analysis also revealed other preoperative independent risk factors for organ space SSIs, including: overweight and obesity at a BMI of 25.0-29. 9 Sepsis and septic shock: high-versus low-risk diagnoses A total of 13.7% of all PD patients experienced sepsis or septic shock. A high-risk diagnosis was associated with a significantly greater incidence of sepsis and septic shock than a low-risk diagnosis (19.1% versus 11.0%; P < 0.001). Multivariate analysis revealed a high-risk diagnosis to be an independent risk factor for sepsis and septic shock (OR 1.83, 95% CI 1.49-2.25).
Other Other preoperative independent risk factors for a prolonged LoS identified in multivariate analysis included: age ≥75 years versus age of 50-64 years (OR 1.58, 95% CI 1.27-1.96), dyspnoea (OR 1.38, 95% CI 1.04-1.83), and preoperative serum albumin of < 3.5 g/dl (OR 1.78, 95% CI 1.48-2.14). Fourth-quartile total operative time (≥ 7.25 h) in comparison with operative time of < 4.75 h was also an independent risk factor (OR 1.68, 95% CI 1.34-2.10).
Other patient outcomes: high-versus low-risk diagnoses Multivariate analysis identified no differences between the highand low-risk diagnosis groups with respect to the occurrence of UTIs, reoperation, 30-day mortality or readmission.
Discussion
In this analysis of multicentre data, outcomes in 5537 patients after PD were associated with these patients' underlying diagnoses. Although the patients in the low-risk diagnosis group had an increased incidence of traditional risk factors for postoperative complications, patients in the high-risk group were identified as having increased risk for complications including a prolonged LoS, organ space infection, sepsis or septic shock and major morbidity. Additionally, this study demonstrated that despite the significant increase in the rates of adverse events associated with diagnosis, there was no corresponding difference in RVU assignment between the high-and low-risk diagnosis groups. Therefore, this study has considerable implications because diagnosis is a non-modifiable, independent risk factor for the occurrence of complications following PD and thus facilitates the calculation of added requirements for complex care and resource utilization in high-risk patients.
Recently, there has been increasing interest in risk calculators for surgery, including PD. 12, 13, 15, 26, 27 Existing risk calculators for PD vary based on the parameters suggested as inputs. Some are designed to include only preoperative variables, whereas others are meant to use an intraoperative assessment. These calculators are very useful for aiding pre-and intraoperative decision making, as well as for providing insight into the relative relationships among different risk factors. They are, however, subject to several limitations. Both forms require time and access to the information required. Preoperative risk calculators require a number of inputs, many of which may not be known. They also, by their very nature, are unable to accurately account for critically important variables such as gland texture and duct size. Diagnoses are either not considered or are generically grouped as 'benign' or 'malignant' . Intraoperative risk calculators include important, albeit subjective, parameters (i.e. gland texture, estimated blood loss), yet these are limited by inter-observer variability. Furthermore, external independent validation of such risk calculators is currently lacking. Existing calculators may also be too complex to allow for simple integration into risk stratification systems and the modification of value assignments. Although risk calculators may prove to be more sensitive or specific for predicting postoperative complications, their use is certainly more complex than the method of stratifying by diagnosis alone. As there is a plausible underlying pathological basis for the inherent risk for complications after PD, risk calculators should certainly incorporate the influence of diagnosis. Further, in an effort to improve the relative value assignment, it may be more prudent to assign additional value to a patient undergoing PD with a 'high-risk' underlying diagnosis than to base it on the sum of a more subjective risk calculator. Currently, in the USA, RVUs are assigned by the Relative Value Update Committee (RUC) to individual operations on the basis of physician work effort. The Centers for Medicare and Medicaid Services (www.CMS.gov) provide a physician fee schedule search tool which allows the RVU for a given CPT to be queried by year. 28 The NSQIP dataset contains total (index and concurrent operations) work RVU data, but these have not been utilized to evaluate PD outcomes. A historical comparison of RVUs assigned for PD as provided by CMS.gov with the total work RVUs reported by the NSQIP shows that the RVU assignments from neither source have increased greatly over time, but that the NSQIP-reported total RVU has increased at a slightly greater rate than that reported by CMS.gov for PD. The increase in total RVU reported in the NSQIP over that seen in the CMS.gov physician fee schedule may potentially be explained by an increase in concurrent operations. For the purposes of this study, patients with concurrent operations that are not typically performed with PD were excluded. However, concurrent operations more typically performed, such as vascular resection, were included and may potentially explain this difference although this study did not specifically investigate the incidence of concurrent operations. Its analysis of total work RVU by diagnosis did demonstrate there to be no relationship between RVU assignment and diagnosis, complications experienced and, therefore, resource utilization. These results were anticipated because there is currently no modification of RVU assignment for operations, including PD, based on diagnosis, risk or actual complications encountered. Diagnosis, as a non-modifiable independent risk factor for patient outcomes and resource utilization after PD, may facilitate a more appropriate assignment of relative value.
Current demands for quality and outcomes improvement require not only a multidisciplinary team-based approach, but also proper patient selection and stratification. Patient stratification involves the identification of both modifiable and nonmodifiable risk factors, and is essential to developing proper individualized patient-centred approaches and ensuring highquality outcomes. Proper patient stratification is also essential to a more accurate reflection of outcomes and takes into account case mix variation. Institutional quality metrics are increasingly used to assess the care provided. Such quality metrics should therefore be adjusted for institutional case mix variation. For example, a case mix consisting primarily of high-risk patients would be expected to have considerable differences in outcomes, resource utilization and complexity of care compared with a case mix of primarily low-risk patients. Furthermore, externally reported performance measures, payer value assignment and performancerelated compensation should also take into account these nonmodifiable risk strata to more accurately account for variation in case mix and complexity of care.
Limitations
This study has several potential limitations. Firstly, this is a retrospective review of a prospective database. Although the ACS has put in place stringent quality control measures to maintain the integrity of the data, such datasets are subject to inherent limitations. Additionally, the database does not contain information on PD-specific variables such as pancreatic fistula, delayed gastric emptying, pancreas texture and duct size. There are also no hospital-or surgeon-specific variables to enable comparisons by volume or experience. This study relies on ICD-9 diagnosis codes for patient identification and thus only the codes for diagnoses that are clearly related to the diagnosis categories created can be studied. The ACS-NSQIP captures only the primary diagnosis and thus only patients with a primary diagnosis representative of a diagnosis of interest could be identified. Further, the ICD-9 diagnosis information in the ACS-NSQIP is limited to one postoperative diagnosis code per patient. The ACS-NSQIP database does not contain preoperative diagnoses and as a result no correlation between pre-and postoperative diagnoses can be made. However, modern preoperative diagnostic modalities make it increasingly common to have a correct diagnosis preoperatively.
Several ICD-9 codes were not included because they either did not translate directly into a defined diagnostic category commonly referenced or were not exclusive to one particular diagnosis. For example, IPMN, serous cystic neoplasm and mucinous cystic neoplasm do not have specific ICD-9 codes and therefore were not evaluated in this study. In addition, although the present authors assigned codes to the created categories to the best of their ability, there is no objective way to evaluate the extent to which the categories are mutually exclusive. Notwithstanding these limitations, however, this is the first large multicentre analysis to evaluate the impact of diagnosis on postoperative outcomes following PD.
Conclusions
This study demonstrates that patients undergoing PD can be easily stratified into high-and low-risk groups based on diagnosis alone. This non-modifiable parameter allows a clinically useful stratification that can be applied at any time in the clinical course of the patient. The present findings suggest that future outcomes studies, performance measures, value assignment, and the obtaining of patient-informed consent for PD should include diagnosis, or diagnosis risk group, as a predictive factor. The reporting of outcomes of PD without such stratification may represent a missed opportunity to improve risk prediction and anticipate resource needs.
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